Collegium Pharmaceutical Inc (COLL)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.00 | 6.98 | 4.86 | 5.02 | 5.85 | 6.58 | 6.05 | 6.76 | 6.03 | 6.09 | 6.30 | 6.36 | 3.41 | 2.95 | 2.82 | 3.80 | 3.46 | 3.73 | 4.15 | 4.50 |
Collegium Pharmaceutical Inc's solvency ratios, including Debt-to-assets ratio, Debt-to-capital ratio, Debt-to-equity ratio, and Financial leverage ratio, have shown consistent and significant improvement over the years. The Debt-to-assets ratio has remained at 0.00 consistently, indicating that the company has no debt relative to its total assets, reflecting a strong financial position.
Similarly, the Debt-to-capital ratio and Debt-to-equity ratio have also stayed at 0.00 throughout the analyzed period, suggesting a conservative capital structure with no significant reliance on debt. This signifies a lower financial risk for the company and a higher level of financial stability.
Furthermore, the Financial leverage ratio has shown a decreasing trend from 4.50 in March 2020 to 1.00 in December 2024. This decline demonstrates a reduction in the company's reliance on debt financing over time, contributing to improved financial flexibility and a stronger solvency position.
Overall, the consistent and favorable solvency ratios of Collegium Pharmaceutical Inc indicate a healthy financial standing and efficient management of its capital structure to support future growth and sustainability.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 2.33 | 2.81 | 2.94 | 2.64 | 1.91 | 1.25 | 0.93 | 0.61 | 0.54 | -0.26 | -0.56 | -0.64 | 0.84 | 2.78 | 2.68 | 2.43 | 1.95 | 1.84 | 1.03 | -1.30 |
The interest coverage ratio measures a company's ability to meet its interest obligations on outstanding debt. A higher ratio indicates a stronger ability to cover interest expenses with operating income.
Based on the provided data for Collegium Pharmaceutical Inc, the interest coverage ratio fluctuated over the reported periods. It declined from negative values in March 2020 and June 2022 to positive levels in subsequent periods. Notably, the ratio improved consistently from September 2020 to June 2024, peaking at 2.94 in June 2024.
However, the ratio dropped slightly in September and December 2024 but remained above 2, indicating the company's ability to comfortably cover interest payments with its operating income.
Overall, Collegium Pharmaceutical Inc demonstrated an upward trend in interest coverage over the analyzed periods, suggesting an improved capacity to handle its interest obligations efficiently.